Avalo Therapeutics (AVTX) EBITDA Margin (2016 - 2024)
Historic EBITDA Margin for Avalo Therapeutics (AVTX) over the last 10 years, with Q4 2024 value amounting to 6932.81%.
- Avalo Therapeutics' EBITDA Margin fell 55916600.0% to 6932.81% in Q4 2024 from the same period last year, while for Sep 2025 it was 40525.52%, marking a year-over-year decrease of 396172300.0%. This contributed to the annual value of 15535.6% for FY2024, which is 141140300.0% down from last year.
- Avalo Therapeutics' EBITDA Margin amounted to 6932.81% in Q4 2024, which was down 55916600.0% from 9251.81% recorded in Q3 2024.
- Over the past 5 years, Avalo Therapeutics' EBITDA Margin peaked at 9251.81% during Q3 2024, and registered a low of 8202.28% during Q4 2021.
- For the 5-year period, Avalo Therapeutics' EBITDA Margin averaged around 1634.39%, with its median value being 1238.35% (2022).
- In the last 5 years, Avalo Therapeutics' EBITDA Margin plummeted by -71108300bps in 2021 and then skyrocketed by 114670600bps in 2024.
- Quarter analysis of 5 years shows Avalo Therapeutics' EBITDA Margin stood at 1091.45% in 2020, then crashed by -652bps to 8202.28% in 2021, then soared by 88bps to 988.28% in 2022, then crashed by -36bps to 1341.16% in 2023, then crashed by -417bps to 6932.81% in 2024.
- Its EBITDA Margin stands at 6932.81% for Q4 2024, versus 9251.81% for Q3 2024 and 1341.16% for Q4 2023.